« Back to Record
Citation APA

Goldhirsch, A., Gelber, R., Piccart-Gebhart, M., de Azambuja, E., Dal Lago, L., Procter, M., McFadden, E., Suter, T., Jackisch, C., Cameron, D. A., Weber, H. H., Heinzmann, D., Dowsett, M., Untch, M., Gianni, L., Bell, R. H., Köhne, C. H., Vindevoghel, A., Andersson, M., Brunt, A. M., Otero-Reyes, D., Song, S., Smith, I., Leyland-Jones, B., & Baselga, J. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial. Lancet, 382(9897), 1021-1028. doi:10.1016/S0140-6736(13)61094-6


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/183184

Goldhirsch, A., Gelber, R., Piccart-Gebhart, M., de Azambuja, E., Dal Lago, L., Procter, M., McFadden, E., Suter, T., Jackisch, C., Cameron, D. A., Weber, H. H., Heinzmann, D., Dowsett, M., Untch, M., Gianni, L., Bell, R. H., Köhne, C. H., Vindevoghel, A., Andersson, M., Brunt, A. M., Otero-Reyes, D., Song, S., Smith, I., Leyland-Jones, B., & Baselga, J. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial. Lancet, 382(9897), 1021-1028. doi:10.1016/S0140-6736(13)61094-6